Background
Study Design and Methods
The PMCA methodology was used to detect prion infection in blood samples obtained from mice experimentally infected with prion disease. Mice were culled at various time points throughout the incubation period for disease and subjected to serial PMCA (sPMCA). Amplified samples were then analysed by western blotting to confirm the presence or absence of infection.
Results
After sPMCA, blood samples from RML-infected mice showed amplification of PrP Sc to levels readily detectable by western blotting. Control samples obtained from mice mock inoculated with sterile PBS did not yield any amplification products.
Conclusion Introduction
Prion diseases are fatal neurodegenerative disorders that included bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and Creutzfeldt-Jakob disease (CJD) in humans 1, 2 . The crucial step in the transmission and propagation of prion diseases, according to the protein-only hypothesis 3 is the conversion of the host's normal, cellular form of the prion protein (PrP C ), via a post-translational process to a protease-resistant, aggregated form (PrP Sc ) 4 . Detection of disease-associated PrP Sc is the most widely used and specific criterion for the diagnosis of prion disease in humans and animals 1, 2 .
Recent studies have shown that significant prion infectivity is present in non-neuronal or lymphatic tissues, such as blood and urine 5, 6 which suggests the potential risk of prion infection via a range of different tissues. In fact, current evidence suggests that blood transfusions may provide an effective route of transmission for prion infection in humans as well as animals [7] [8] [9] [10] . Taken together with the extended length of the pre-clinical period of vCJD, transmission of vCJD via transfusion or other iatrogenic means has become an issue of public concern. Therefore a diagnostic test which can be applied to the rapid screening of transfusion samples as well as blood products is highly desirable. 11, 12, [20] [21] [22] the total infectivity partitioned into this fraction is only about one third of the total in whole blood.
With this in mind we set out to adapt PMCA to use whole blood as the seed for our amplification, as this is the most practical material to use for blood screening and will contain the infectivity associated with all fractions. Substrate homogenates for amplification were generated from the brains of transgenic Tg20 mice which overexpress 
Methods

Tissues samples
All procedures were carried out in a microbiological containment level III facility with strict adherence to safety protocols. 26, 27 . Tissue homogenates were stored as aliquots in eppenforf tubes at -80°C. Preparation of PMCA substrate homogenates is detailed below. Whole normal blood was collected from uninfected CD1 mice.
Time course of RML infection in CD1 mice
RML time course of infection was performed by inoculating CD1 mice inter-cortically 
Western Blotting
Samples were analyzed by electrophoresis and immunoblotting following Proteinase K digestion (200 μg/ml final protease concentration) as described previously 27, 29 . and signal intensity of bands was quantified using Imagequant software (Molecular Dynamics).
Protein Misfolding Cyclic Amplification
Protein Misfolding Cyclic Amplification (PMCA) was performed as described previously 16 . Briefly, 10% (w/v) PMCA substrate homogenates were prepared from Tg20 mice brains which had been perfused with PBS containing 5 mM EDTA at the time of death.
Brains were homogenised in cold conversion buffer (PBS containing 150mM NaCl, 1.0%
Triton X-100, 4mM EDTA and Complete Protease Inhibitor Mixture (Roche Applied Biosciences)). Substrate homogenates were clarified by centrifugation at 1000 g for 45 seconds and then stored at -70°C without freeze-thawing until required. RML infected homogenate was diluted into 100 µl of substrate homogenate in 0.2 ml PCR tubes and 40 µl retained as minus PMCA controls. Samples were subjected to 140 cycles of PMCA consisting of a 20 second pulse of sonication at 75% power output using a Misonix S3000 sonicator with a microplate horn (Misonix, Farmingdale, USA) followed by incubation for 30 minutes at 35 o C. In serial PMCA experiments, samples were subjected to successive rounds of 140 PMCA cycles followed by 1:10 dilution into fresh substrate homogenate.
For PMCA of RML time course and normal blood samples, 1µl of pooled whole blood from 140 day post-infection and uninfected animals was diluted 1:100 into PMCA substrate homogenate. After mixing, 40 µl was removed and stored at -70°C as a PMCA minus control. Samples were subjected to serial PMCA as described above. All samples were analysed by PK digestion (200 µg/ml final protease concentration for 60 minutes at 37°C) and Western blotting.
Results
Serial PMCA of RML infected brain homogenates
To determine the extent of amplification within our PMCA experiments we performed serial PMCA on RML infected CD1 brain homogenates diluted into transgenic Tg20 23 substrate homogenate. RML homogenate was diluted 400 fold and subjected to 140 cycles of PMCA. Further dilutions (10, 100 and 200 fold) were performed into fresh substrate and two subsequent rounds of sPMCA were undertaken ( Figure 1 ). In all cases PrP Sc was amplified efficiently, with a 20 to 40 fold increase in PK resistant material at each sPMCA step when compared to the PK resistant PrP in samples which were not subjected to PMCA. Overall the total amplification achieved was > 16000 fold at the highest dilution, confirming our PMCA system using transgenic murine brain homogenate as the substrate is an efficient means of amplifying mouse PrP RES .
Amplification of PrP Sc spiked into normal whole blood
To establish the efficacy of our Tg20 system to amplify PrP RES out of whole blood, we prepared samples containing RML homogenate diluted into either normal CD1 homogenate or whole blood. These were then used to seed Tg20 PMCA substrate homogenates (1 µl into 100 µl) giving a final dilution of seed RML of 400 and 800 fold 
Discussion
Here we detail the first amplification of PrP RES from whole blood and the clinical discrimination between normal and prion infected pre-symptomatic animal bloods.
Although PrP RES has been successfully amplified from blood leukocyte preparations in rodents and sheep [17] [18] [19] by PMCA, buffy coat is unlikely to be a plausible analyte for a blood screening assay that can be utilised on a large scale due to the prohibitive time and complexity for preparation. Whole blood represents a more practical material for a blood test as well as being guaranteed to contain the entirety of PrP and prion infectivity in the sample. These results suggest that with carefully optimisation for human PMCA it should be possible to distinguish between normal blood and that from vCJD patients.
Despite these promising results, PMCA still remains a technically challenging procedure.
As well as obvious problems such the time consuming nature of serial PMCA and the possibility of de novo generation of PrP RES 19, 24 , choosing the ideal substrate for testing is crucial. In our experiments there is a significant inhibition of amplification (~50%) in the 13, 32 . However, unlike PMCA these reactions do not result in the replication of prion infectivity, questioning their fidelity and they may be significantly more susceptible to false positive results from other amyloidoses.
The detection of PrP Sc in blood is considerably more challenging than other tissues with as little as 10 infectious units present in 1ml of whole blood. In order to achieve the high levels of sensitivity required a blood-based CJD diagnostic assay will need to exploit the unique ability of prions to replicate and incorporate an in vitro amplification step in the methodology. However, amplification alone does not provide a solution to blood based diagnosis due in part to the low abundance of PrP Sc requiring large volumes of blood to be sampled to obtain certainty that at low titres during pre-clinical stages of infection a prion particle is certain to be present. In addition the experimental complexities and time scales of amplifying from low titre analytes would preclude the use of amplification alone as a screening assay. It is likely that a combination of enrichment, amplification and high sensitivity detection will be required to reduce the time scales involved and robustly provide the very high levels of sensitivity and specificity required of a blood screening assay.
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